Flex Pharma (FLKS) Commences FLX-787 Phase 2 in AML
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Flex Pharma, Inc. (NASDAQ: FLKS) announced that it has initiated a Phase 2 efficacy study in amyotrophic lateral sclerosis (ALS) patients in Australia with FLX-787, its chemically synthesized, single molecule, transient receptor potential (TRP) ion channel activator, formulated as an oral tablet. The randomized, controlled, blinded, cross-over study is designed to evaluate the safety and efficacy of FLX-787 in patients who suffer from cramps and/or spasticity as a consequence of ALS.
ALS is a neurological disease that causes muscle weakness and impacts physical function. ALS often begins with muscle twitching and weakness in an arm or leg, or sometimes with slurring of speech. Eventually, ALS can affect the ability to control the muscles needed to move, speak, eat and breathe. ALS patients commonly experience fasciculations, which are persistent muscle twitches that can interfere with sleep, and over half of all patients with ALS also experience painful muscle cramps that can significantly decrease their quality of life. Based on a report published by the Centers for Disease Control, we estimate that over 12,000 people in the United States suffer from ALS.
“We have initiated three human efficacy studies this year – in nocturnal leg cramps, multiple sclerosis and now ALS – with our single agent candidate, FLX-787,” said Flex Pharma Chief Medical Officer Thomas Wessel, M.D., Ph.D., who served as the medical lead for three products approved in United States: Razadyne®, Lunesta® and Ampyra®. “We are hopeful that our efforts will ultimately help the many patients with severe neuromuscular diseases who suffer from these painful conditions.”
“Topical Chemical Neuro Stimulation is a process whereby small molecules activate TRP ion channels on sensory nerves in the oral mucosa, which we hypothesize signal through neural circuits to inhibit the hyperexcitable motor neurons in the spinal cord that can cause muscle cramps,” noted Dr. Rod MacKinnon, Nobel laureate and Flex Pharma Scientific Co-Founder, Board Member, and Scientific Advisory Board Co-Chair. “We hypothesize that this approach may be generally applicable as a treatment for cramps and spasms in a spectrum of neuromuscular conditions.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex Pharma (VRTX) Announces Positive Longer-Term ORKAMBI + KALYDECO Data in CF Progression Modification
- General Electric (GE) Secures $900M+ Turnkey Order with Brazil's CELSE for Sergipe Power Plant
- Pinnacle Foods (PF) Names New Corp. Development SVP
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!